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Improvement of leucocytic NaK pump activity in uremic patients on
low protein diet. Leucocytic NaK pump activity was assessed in 20
patients with advanced renal failure. NaK-ATPase activity was
reduced when compared with the values obtained from normal subjects
(101.8 48.6 versus 165.13 8.9 tM of Pi hr g;P <0.001) and
the mean 86Rb uptake by U 937 cells was depressed by 38% after the
addition of patients' sera. Subsequently, patients were put on a diet
providing 0.3 g protein/kg body weight daily and supplemented with
ketoacids. After three months of dietary treatment NaK-ATPase
activity increased to 142 48,3 (P < 0.01) and reached normal values
at the sixth month (162.8 54.70 M of Pi hr g; P < 0.001)
whereas 86Rb uptake increased by 23 percent when compared to initial
values. These data suggest that among the different mechanisms which
have been advanced to explain the defects in the Na pump observed
in uremic patients, circulating inhibitors deriving from alimentary
protein intake may affect cation transport.
Passage of ions across the cell membrane is permitted by the
presence of genetically-coded specific proteins, the most impor-
tant being the NaK pump that maintains the transmembrane
gradient for these ions. Dysfunction of this pump can result in
many adverse consequences for cellular metabolism.
In 1964, Welt, Sachs and McManus demonstrated, in a
pioneering study, a reduced cation transport in erythrocytes of
patients with chronic renal failure (CRF) [1]. Three years later,
Welt et al [2] showed in a subgroup of uremic patients that the
salt and water content of erythrocytes was increased. This was
coupled with a reduced sodium efflux and a reduction of the cell
membrane ATPase activity. The depression in pump activity
observed after incubation of normal erythrocytes with uremic
plasma suggested the existence of a circulating pump inhibitor
in patients with CRF [3]. Since then, several works have
confirmed, to varying degrees, these results. In a recent paper
[4], Stokes et al found evidence for inhibition of the erythrocyte
sodium pump in 11 of 15 studies determining the pump activity
in uremic patients.
Initial work was performed on the erythrocyte because of its
availability and convenience, but leucocytes [5], skeletal mus-
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cle [6], intestinal epithelia [7], and brain tissue, as well as
neurones [8, 9] and heart cells [10], have shown comparable
alterations in Na pump activity.
These defects seem to be corrected by hemodialysis [11—13].
Moreover, in the study by Cotton et al [6], the electrochemical
changes observed in the muscle cells of uremic patients were
reversed by intensive hemodialysis (HD) and recurred when
dialysis time was reduced, then returned again to normal
(despite the fact that the frequency of HD remained un-
changed), when the alimentary protein intake was reduced to
0.5 glkg/day [14].
These last results inspired us to assess the effects of a low
protein diet supplemented with ketoacids (LPD) on the Na
pump activity of leucocytes in uremic patients not requiring
dialysis therapy.
Methods
Patients
Twenty ambulatory patients (15 men, 5 women) ranging in
age from 22 to 68 years, with advanced renal failure [glomerular
filtration rate (GFR) 14.9 6.2 ml/min/1.73 ml were studied.
The clinical and laboratory characteristics of the patients are
depicted in Table I. None of them were treated by cardiac
glycosides or diuretics during the previous months or follow-up.
Before the study all patients had followed a diet supplying daily
between 0.8 and 1 g proteinlkg body weight and 100 to 150 mEq
sodium.
The patients began a low protein diet (LPD) providing 0.3 g
protein of vegetal origin and 3 to 5 mg inorganic phosphorus per
kg body weight daily. Salt intake was not significantly modified.
The calorie supply (approximately 35 KCallkg/day) was fur-
nished mainly by carbohydrates (67% of calories), while lipids
accounted for approximately 30% of the calorie intake (Table
2). In patients with heavy proteinuria, each gram of urinary
protein loss was replaced with an additional 1.25 g of protein
with a high biological value of animal origin in the diet. The diet
was supplemented with a mixture of essential amino acids and
ketoanalogues (Ketosteril, Fresenius Germany), the daily dose
being one tablet per 5 kg body weight, and each tablet providing
36 mg of nitrogen and 50 mg of calcium. All patients were
supplemented daily with I g calcium carbonate, oral iron and a
multivitamin preparation. As a control group for normal values,
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Table 1. Characteristics of patients at the start of the study
Number of patients 20
Age years 54.1 14.8
Sex(M-F) 15—5
GFR mi/mn 14.9 6.2
Underlying renal disease
Chronic glomerulonephritis 6
Chronic pyelonephritis 8
Benign nephrosclerosis 3
Polycystic kidney disease I
Unknown 2
15 students and staff members of the department ranging in age
from 23 to 53 years were studied. All patients had given prior
consent to the procedures of the study.
Follow-up laboratory techniques
All patients were followed every month by measuring body
weight, triceps skinfold thickness, blood pressure, serum cre-
atinine, urea, electrolytes, alkaline phosphatase, triglycerides,
total protein, albumin, iron, parathormone (intact hormone),
and urinary creatinine, urea, electrolytes, phosphorus and
protein. Sera were stored at —80°C. GFR was measured using a
single isotope technique: 5tCr-Ethylenediamine tetraacetate
(51Cr-EDTA) which was administered into a forearm vein.
Samples of venous blood were withdrawn from the contralat-
era! forearm at 15, 45, 75, and 105 minutes after injection and
urines were collected at 0, 30, 60, 90, and 120 minutes after
injection. 51Cr EDTA clearance was calculated using the stan-
dard clearance formula.
Measurement of Na K
-A TPase activity of leucocytes
The NaK-ATPase activity of human leucocytes was as-
sayed by measuring the release of inorganic phosphate (P1) from
ATP with an automated stannous chloride/hydrazine procedure
[15] under the optimal conditions described by Baron and Khan
[16]. Leucocytes form peripheral venous blood (40 ml) were
prepared by dextran sedimentation and hypotonic lysis of
erythrocytes and then lysed by sonication. Protein content was
determined in an aliquot of each sample. The maximum enzyme
activity was achieved under the following conditions: buffer
composition Tris-HC1 50 mrs, NaCI 100 mts, KC1 15 mM, MgCI2
7 m, ATP 5 mr.t, EDTA 1 mr'.i (pH 7.2) at 37°C. NaK-
ATPase activity was calculated as the difference between
inorganic phosphate (P1) released by the action of leucocyte
samples on ATP in the presence and absence of ouabain (final
concentration 100 /.LM in aqueous ethanol 9 mM).
Culture of U 937 cells
The U 937 cell line was chosen because this mature cell line
has functions close to normal leucocytes [17]. U 937 cells were
cultured in RPMI 1640 medium containing Hepes (25 mM), L
glutamine (2 mM), penicillin (100 U/mI), and streptomycin (100
.&g/ml) and supplemented with 10% fetal calf serum (FCS) (all
from Gibco-Europe, Paisley, UK) in tissue culture flasks (F
3013; Falcon Plastics, Oxnard, California, USA) at 37°C in a 5%
CO2 atmosphere.
Aliquots of U 937 cells were cultured in RPM! medium
supplemented with 10% human serum from patients or control
subjects for 24 hours before 86Rb uptake assay.
Table 2. Characteristics of low protein diet
Calorie supply Kca!/kg/day 35
% from carbohydrates 67
% from lipids 30
% from proteins 3
Protein content g/kg/day 0.3
Phosphorus content mg/kg/day 3—5
Supplemented with
A mixture of EA-KA (Ketosteril Fresenius, Germany)
one tablet for 5 kg body weight, each tablet
providing 36 mg of nitrogen and 50 mg of calcium
Calcium: 0.5—I g in salt form
Multivitamin preparation (1000 U vitamin D)
Iron
86Rubidium uptake by U 937 cells
Cells were washed three times in a potassium-free Ringer
solution (NaCI 143 mrt, CaCl2 1.34 m, glucose 5 m, Mg SO4
1.26 m buffered at pH 7.2 with phosphate buffer: Na2H
P04-NaH2 P04 110 mM) adjusted to l0 per tube and mixed with
Ringer solution containing 86Rb 3 M (initial radioactivity: 4
mCilmg Amersham, Les Ulis, France) for tne hour at 37°C,
washed six times and counted in a gamma counter (Auto
Gamma Scintillation Spectrometer Packard Instruments,
Rungis, France) according to the method of Aronson et al [18].
Statistical analysis
Two-tailed Student's t-tests for paired samples were used to
analyze the results at the start and end of the study. After
Bonferroni's correction for multiple t-tests in one group, P
values less than 0.01 were considered to be significant.
The effect of LPD on NaK-ATPase activity was analyzed
by one way (time) analysis of variance. Results are expressed as
mean SD.
Results
No adverse effects were encountered and compliance with
the prescribed diet, assessed by regular interviews and monthly
measurements of urinary urea, phosphorus and sodium excre-
tion was satisfactory in most patients. The urinary urea excre-
tion, which was 235.9 67.2 mmol/24 hr at the start of the study
decreased to 64.8 24.8 mmol/24 hr (P < 0.001) at the end of
the third month, and was maintained throughout the follow-up
(71.6 33.7 mmol/24 hr at the 12th month). The estimated mean
protein intake evaluated by Maroni, Steinman and Mitch's
formula [19] was 0.35 g/kg body weight. Body weight and
anthropometric data, serum protein and serum albumin re-
mained stable during the one year follow-up. At the end of the
survey blood urea had decreased from 22.5 8.2 to 7.6 3.5
mM/liter (P < 0.0001). Serum creatinine remained unchanged,
424.6 131.9 versus 420.2 164.1 SM/liter (NS), while GFR
decreased from 14.9 6.2 to 12.4 6.1 mllmn (P < 0.01).
Serum bicarbonate returned to normal values, from 23.6 4.6
to 26.7 2.8 mM/liter (P < 0.01). Serum parathyroid hormone
(PTH) decreased from 161 97.2 to 95.8 56.6 pg/mI (P <
0.005; Table 3).
NaK-ATPase
At the start of the study, a significant reduction of mean
NaK-ATPase activity was observed when compared with
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Table 3. Outcome of blob gical parameters after 12 months of LPD
0 Month 12 Month P
Serum urea mM/liter 22.5 8.2 7.6 3.5 <0.001
Serum creatinine pm/liter 424.6 131.9 420.2 164.1 NS
GFR mi/mn 14.9 6.2 12.4 6.1 <0.01
Serum C03H mM/liter 23.6 4.6 26.7 2.8 <0.01
PTH pg/mi 161 97.2 95.8 56.6 <0,005
the values obtained from normal subjects (101.8 48.6 vs.
165.1 8.9 /.LM of P1 hr g; P <0.001). ATPase activity was
lower than that of the average control value in 16 of the 20
patients. The mean patient/control ratio for ATPase activity in
the entire uremic group was 0.55 (P <0.01). No correlation was
found with either GFR (r = 0.06), mean arterial blood pressure(r = 0.27) or serum PTH (r = 0.18).
On LPD, mean NaK-ATPase activity increased signifi-
cantly (P <0.0001), from 101.8 48.6 pM P1 hr g to 142
48.3 at the third month, to reach normal values at the sixth
month (162.8 54.7) which were maintained at the ninth month
(172.3 55) and at the end of the follow-up (177.9 47.8; Fig.
1).
8R/, uptake
No difference in morphology and cell count of U 937 cells
cultured 24 hours in RPM! medium supplemented with human
serum, from the control or the study group, was observed for
any serum in comparison with control cultures in the same
medium supplemented with FCS. 86Rb uptake of U 937 cells
was linear for 120 minutes. A 60 minute incubation in a
potassium-free Ringer solution was selected, as this incubation
time did not modify U 937 cell viability.
At the start of the study, after incubation with patient's sera,
a significant reduction of mean 86Rb uptake by U 937 cells was
observed when compared with the values obtained after incu-
bation with sera from control group (66.7 14.8 vs. 93.6 2.8
nmol/109 cells/hr). After three months of dietary treatment, the
mean rate of 86Rb influx increased by 23%, from 66.7 14.8 to
82 17.3 nmol/109 cells/hr (P < 0.0001; Fig. 2).
As prolonged storage might affect serum properties, we
verified that no differences in 86Rb uptake by U 937 cells were
observed by companng sera from the reference group freshly
withdrawn or stored at —80°C for three to six months.
Discussion
Our observations confirm a reduced Na pump activity in
patients with advanced renal failure, and show the correction of
this impairment by reduction in phosphorus and protein intake
in spite of a continuous progression of renal insufficiency.
Na pump defect
We studied the leucocytic Na pump function by measuring
the NaK-ATPase activity and the sodium pump-mediated
cation flux. As in previous studies we observed a significant
reduction in Na pump activity in uremic patients through
these two parameters. The mean patient/control ratio for oua-
bain-senisitive ATPase activity was 0.55, close to the ratio of
0.62 observed by Cole in erythrocytes [20], and by Swami-
nathan et al [21] and Kramer, Gospodinov and Kruck [221 in
erythrocyte hemolysates. As others [23, 24], we did not find
individual correlations between NaK-ATPase activity and
renal function or mean arterial blood pressure.
U 937 cells incubated in medium supplemented with patients'
sera for 24 hours showed a mean reduction in 86Rb uptake of
38% when compared to results obtained after incubation in
media supplemented with human serum from the control group.
A similar reduction in 86Rb uptake by uremic human erythro-
cytes or by synaptosomes, adipocytes and muscle cells from
uremic rats has been reported by different authors [9, 25, 26]. In
another study [13], normal erythrocytes incubated in uremic
plasma showed a 20% reduction in ouabain-sensitive K influx.
Conversely, Cheng et al [27] found that the 42K-pump influx
was not significantly different in uremic erythrocytes compared
with erythrocytes from normal subjects.
After three months on a LPD, leucocyte NaK-ATPase
activity increased significantly, becoming normal at the sixth
month. At the same time 86Rb uptake by U 937 cells incubated
with patients' sera improved significantly when compared to
initial values. It is noteworthy that a similar improvement has
been observed in most studies when patients benefited from
intermittent hemodialysis therapy [6, 13, 24, 251.
Mechanisms
It would surely be erroneous to invoke a single mechanism to
explain Na pump defects. Indeed, beginning with the earliest
publication it has been observed that alterations of the Na
pump during CRF are not constant. Furthermore, all cells and
tissues are not equally affected and the mechanisms of this
functional alteration are known to vary according to the tissues
involved.
As primary abnormality, a decrease in intracellular ATP
concentration [28], a reduced number of Na pump units [23,
24] or an increased intracellular sodium concentration [22, 271
have been advocated to explain the malfunctioning of the Na
pump.
Intracellular ATP concentration has been found elevated,
normal or decreased according to the different cells and tissues
studied [8, 28]. In our study, the responsibility of a deficit in the
pump's energy substrate can be ruled out, since an optimal
concentration of ATP (5 mM) was imposed for the assay of
Na K -ATPase activity in leucocytes.
Studies concerning Na pump units have given various and
controversial data concerning their numbers as well as their
relationship with the intracellular sodium content or with the
sodium pump-mediated cation flux [23, 24].
High internal sodium concentrations have not been found in
all studies. In the initial work of Welt et al, [21 only 25% of
patients presented elevated erythrocyte sodium concentrations,
and these patients had lower NaK-ATPase activity. In
several other studies in uremic patients, internal Na concentra-
tions have been found to be normal [22, 241 or even low [14]. As
a general rule, there is no strict correlation between internal Na
concentration and ATPase activity.
We did not assess the number of sodium pump units or the
level of intracellular sodium. However, after leucocyte sonica-
tion, the assay of the phosphatase activity of the NaK pump
was not dependent on intracellular sodium concentration, but
rather on the concentration of ATP, which was optimal. More-
over, cation flux rates which were studied by measuring 86Rb
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Fig. 1. Outcome of NaK-ATPase activity
in 20 uremic patients on LPD. P < 0.0001
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uptake by U 937, were depressed by a 24 hour incubation with
10% uremic sera. Although we did not measure the sodium
content of U 937 cells, it was probably close to normal.
Therefore, an increase in intracellular sodium concentration
would be a consequence of the decrease in the activity of the
NaK pump.
Several potential factors are liable to interfere with the Na
pump activity in uremic cells [29].
A possible role of hormones has been proposed because some
of them have been shown to modulate the activity of the
NaK pump in normal subjects [26, 30].
The correction of Na pump defects by HD suggests that
circulating factors could also play a role. Some of them, like
atrial natriuretic peptides [31, 32] or endogenous digitalis-like
substances [33], might act in modulating the urinary sodium
excretion to maintain normal extracellular volume.
The responsibility of uremic toxins has been evoked. We
have observed that urea and some guanidino compounds at
concentrations close to those observed in uremic patients can
reduce 86Rb uptake by myeloid cells (unpublished data). Since
urea, methylguanidine and guanidinosuccinic acid production
are modulated by the dietary protein intake [34], it is possible
that the improvement of leucocytic Na pump activity in
patients on LPD is related to the decreased production of these
toxins. Moreover, Cotton et al [6] showed that the resting
transmembrane potential difference, which decreased when HD
periods were shortened, returned to normal when the alimen-
tary protein intake was reduced, suggesting that toxins that
affect Na pump activity are dialyzable and could have an
alimentary origin [14]. Our study seems to confirm these latter
results.
Conclusion
Abnormalities of Na pump activity in CRF are complex,
multifactorial and may vary according to the affected cell or
tissue. Our prospective, open study is criticizable from a
methodological point of view and deserves to be completed by
a controlled trial. However, among the different mechanisms
usually advanced to explain alterations in cation transport, our
study provides further evidence for the existence of circulating
inhibitors derived from alimentary proteins.
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